Hospital
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $107.94M by Medicaid between Jan 2018 and Dec 2024, across 505 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
HAZARD, KY 41701
HAZARD, KY 41701
33aNPI1609869916assigned 08/23/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$107.94M
24GClaims1,905,556
24DCodes billed505
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#4 of 36
Median peer was paid$36.08M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 348,325 | $17.33M | |
| 2019 | 290,920 | $16.52M | |
| 2020 | 292,464 | $15.39M | |
| 2021 | 319,514 | $14.82M | |
| 2022 | 249,244 | $14.45M | |
| 2023 | 219,805 | $14.25M | |
| 2024incomplete | 185,284 | $15.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 32,304 | 27,246 | $13.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 22,037 | 13,666 | $10.70M |
| G0378 | Hospital observation service, per hour | 8.6% | 26,724 | 14,066 | $9.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 7,929 | 6,808 | $5.68M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.2% | 6,633 | 5,631 | $3.48M |
| 80053 | Comprehensive metabolic panel | 2.2% | 103,969 | 69,570 | $2.33M |
| 93458 | 2.1% | 2,217 | 860 | $2.29M | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 6,008 | 5,283 | $2.28M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 9,690 | 8,019 | $2.25M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.0% | 3,365 | 2,203 | $2.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.9% | 19,717 | 17,717 | $2.06M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 5,305 | 3,121 | $2.00M |
493 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 124,162 | $1.79M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.5% | 3,555 | $1.66M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 112,529 | $1.63M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 17,559 | $1.63M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 32,253 | $1.06M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 21,555 | $941K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,831 | $905K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,038 | $886K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,999 | $857K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,592 | $837K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,594 | $833K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,947 | $785K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 19,776 | $773K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,872 | $770K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,099 | $769K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,005 | $733K |
| 84484 | <1% | 21,965 | $665K | |
| 83735 | <1% | 26,069 | $650K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 265,448 | $637K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,320 | $628K |
| 72131 | <1% | 2,332 | $613K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 9,604 | $611K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,914 | $598K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,380 | $596K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14,983 | $591K |
| 72141 | <1% | 1,309 | $527K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,135 | $506K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,331 | $502K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,044 | $471K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,250 | $469K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,646 | $445K |
| 71250 | <1% | 1,809 | $436K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,634 | $433K |
| 80061 | Lipid panel | <1% | 16,751 | $422K |
| 72128 | <1% | 1,264 | $412K | |
| 87040 | <1% | 9,748 | $410K | |
| 96367 | <1% | 9,817 | $408K | |
| 87631 | <1% | 5,604 | $404K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,789 | $387K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,528 | $376K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,205 | $372K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 658 | $365K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,456 | $364K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,393 | $360K |
| 85730 | <1% | 11,968 | $347K | |
| 82607 | <1% | 11,509 | $342K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 4,786 | $327K |
| 70486 | <1% | 1,293 | $314K | |
| 96376 | <1% | 9,506 | $311K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12,384 | $304K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,230 | $292K |
| 47563 | <1% | 253 | $282K | |
| 73221 | <1% | 639 | $274K | |
| 83690 | <1% | 10,578 | $263K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 547 | $255K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,190 | $254K |
| 74022 | <1% | 2,785 | $252K | |
| 87902 | <1% | 1,084 | $240K | |
| 80074 | <1% | 4,647 | $232K | |
| 81001 | <1% | 30,403 | $228K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 372 | $227K |
| 74018 | <1% | 5,362 | $221K | |
| 85610 | <1% | 16,502 | $215K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,886 | $210K |
| 74178 | <1% | 304 | $208K | |
| 81025 | <1% | 10,420 | $205K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,617 | $203K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 306 | $201K |
| 93971 | <1% | 1,790 | $198K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,472 | $193K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,205 | $188K |
| 73630 | <1% | 4,163 | $186K | |
| 82728 | <1% | 6,003 | $185K | |
| 87522 | Neg quan hep c or qual rna | <1% | 5,213 | $184K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 29,259 | $182K |
| 93041 | <1% | 10,794 | $181K | |
| 71271 | <1% | 599 | $178K | |
| 73610 | <1% | 3,694 | $170K | |
| 73030 | <1% | 4,161 | $166K | |
| 82553 | <1% | 7,542 | $166K | |
| 84702 | <1% | 6,022 | $162K | |
| 84145 | <1% | 3,387 | $162K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,726 | $159K |
| 82150 | <1% | 4,021 | $158K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 703 | $157K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,654 | $156K |
| 78227 | <1% | 839 | $150K | |
| 83605 | <1% | 5,676 | $150K | |
| 72110 | <1% | 2,179 | $143K | |
| 73110 | <1% | 2,909 | $141K | |
| 84439 | <1% | 5,684 | $140K | |
| 72100 | <1% | 3,457 | $139K | |
| 87186 | <1% | 5,653 | $139K | |
| 82550 | <1% | 11,454 | $134K | |
| 73130 | <1% | 2,966 | $134K | |
| 83880 | <1% | 3,971 | $131K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,403 | $130K |
| 88342 | <1% | 1,230 | $130K | |
| 87070 | <1% | 6,683 | $125K | |
| 93970 | <1% | 868 | $125K | |
| 97597 | <1% | 2,146 | $123K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 3,260 | $122K |
| 76536 | <1% | 1,011 | $118K | |
| 43235 | <1% | 282 | $112K | |
| 93880 | <1% | 1,117 | $112K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,024 | $110K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,804 | $107K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,732 | $105K |
| 73564 | <1% | 1,908 | $104K | |
| 80076 | <1% | 4,912 | $102K | |
| 82746 | <1% | 2,781 | $97K | |
| 93017 | <1% | 997 | $97K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,348 | $92K |
| 83540 | <1% | 4,946 | $92K | |
| 96368 | <1% | 1,981 | $91K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,157 | $91K |
| 86140 | <1% | 6,481 | $91K | |
| 83970 | <1% | 1,243 | $90K | |
| 73560 | <1% | 2,183 | $89K | |
| 47562 | <1% | 120 | $88K | |
| 94761 | <1% | 2,641 | $85K | |
| 73562 | <1% | 1,749 | $84K | |
| 59025 | Fetal non-stress test | <1% | 1,791 | $84K |
| 77412 | <1% | 357 | $83K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 197 | $83K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,401 | $82K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 182 | $82K |
| 86038 | <1% | 2,133 | $80K | |
| 73590 | <1% | 1,976 | $79K | |
| 84100 | <1% | 8,437 | $79K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 560 | $77K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 625 | $77K |
| 97035 | <1% | 2,308 | $77K | |
| 83550 | <1% | 3,870 | $71K | |
| 73090 | <1% | 1,774 | $71K | |
| 87517 | <1% | 1,041 | $69K | |
| 73700 | <1% | 293 | $69K | |
| 86706 | <1% | 2,600 | $68K | |
| 82570 | <1% | 2,387 | $68K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,077 | $65K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 141 | $63K |
| 83516 | <1% | 1,701 | $63K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,067 | $62K |
| 84146 | <1% | 1,975 | $61K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,235 | $61K |
| 87340 | <1% | 1,924 | $59K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 533 | $57K |
| 72040 | <1% | 1,450 | $57K | |
| 80299 | <1% | 543 | $57K | |
| 73502 | <1% | 1,820 | $56K | |
| 82140 | <1% | 2,469 | $55K | |
| 97162 | <1% | 1,564 | $55K | |
| 76775 | <1% | 977 | $55K | |
| 85652 | <1% | 5,679 | $53K | |
| 0100U | <1% | 918 | $52K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,595 | $50K |
| 87077 | <1% | 3,884 | $49K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,747 | $49K |
| 83883 | <1% | 1,488 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,732 | $47K |
| 87076 | <1% | 4,797 | $47K | |
| 76830 | Ultrasound, transvaginal | <1% | 387 | $47K |
| 76000 | <1% | 882 | $47K | |
| 82172 | <1% | 1,660 | $45K | |
| 84703 | <1% | 3,287 | $45K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 441 | $44K |
| 82803 | <1% | 1,432 | $43K | |
| 86850 | <1% | 3,711 | $43K | |
| 86803 | <1% | 2,005 | $42K | |
| 12001 | <1% | 558 | $42K | |
| 86704 | <1% | 1,772 | $42K | |
| C1769 | Guide wire | <1% | 2,092 | $41K |
| 73080 | <1% | 842 | $40K | |
| 96417 | <1% | 1,177 | $40K | |
| 76801 | <1% | 209 | $38K | |
| 97014 | <1% | 742 | $37K | |
| 91200 | <1% | 771 | $37K | |
| 97161 | <1% | 980 | $36K | |
| 86900 | <1% | 4,696 | $36K | |
| 97602 | <1% | 828 | $35K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 50 | $35K |
| 76770 | <1% | 530 | $34K | |
| 86901 | <1% | 4,445 | $34K | |
| 72050 | <1% | 701 | $34K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,658 | $33K |
| 95819 | <1% | 299 | $33K | |
| 80305 | <1% | 4,370 | $33K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,161 | $33K |
| 88304 | <1% | 1,576 | $32K | |
| 86708 | <1% | 1,679 | $32K | |
| 72170 | <1% | 823 | $32K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,670 | $32K |
| 82977 | <1% | 2,032 | $31K | |
| 83010 | <1% | 1,688 | $31K | |
| 94060 | <1% | 490 | $30K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 4,044 | $29K |
| 36600 | <1% | 1,376 | $29K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 727 | $28K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,842 | $28K |
| 83615 | <1% | 2,374 | $28K | |
| 82043 | <1% | 2,162 | $27K | |
| 82103 | <1% | 582 | $25K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 213 | $24K |
| 85378 | <1% | 2,111 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,985 | $23K |
| 73565 | <1% | 483 | $22K | |
| 77336 | <1% | 254 | $22K | |
| 80202 | <1% | 802 | $21K | |
| 20610 | <1% | 463 | $21K | |
| 83521 | <1% | 549 | $21K | |
| 62323 | <1% | 115 | $21K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 881 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,847 | $20K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,763 | $20K |
| 86431 | <1% | 751 | $20K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 400 | $19K |
| 82247 | <1% | 1,722 | $19K | |
| 85027 | <1% | 2,271 | $19K | |
| 86200 | <1% | 1,036 | $19K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,246 | $18K |
| 70491 | <1% | 92 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 915 | $18K |
| 84156 | <1% | 1,276 | $18K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 84 | $18K |
| 86480 | <1% | 477 | $18K | |
| 94762 | <1% | 384 | $18K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,785 | $18K |
| 10061 | <1% | 16 | $17K | |
| 84550 | <1% | 1,837 | $16K | |
| 88341 | <1% | 154 | $16K | |
| 80164 | <1% | 1,323 | $16K | |
| 87507 | <1% | 83 | $15K | |
| 87275 | <1% | 1,727 | $15K | |
| 90715 | <1% | 415 | $15K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,536 | $15K |
| 84460 | <1% | 1,507 | $14K | |
| 76642 | <1% | 339 | $14K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 61 | $14K |
| 87634 | <1% | 388 | $14K | |
| 73100 | <1% | 370 | $14K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,868 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,237 | $13K |
| 82947 | <1% | 1,206 | $13K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 82 | $13K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,217 | $13K |
| 82652 | <1% | 510 | $13K | |
| 87350 | <1% | 675 | $13K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 32 | $12K |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 739 | $12K |
| 87590 | <1% | 711 | $12K | |
| 86707 | <1% | 615 | $12K | |
| 72146 | <1% | 42 | $12K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 16 | $11K |
| J3490 | Unclassified drugs | <1% | 1,298 | $11K |
| 73060 | <1% | 258 | $11K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 470 | $11K |
| 81002 | <1% | 2,366 | $11K | |
| 84481 | <1% | 222 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,659 | $11K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,323 | $11K |
| 78454 | <1% | 81 | $11K | |
| 73521 | <1% | 135 | $10K | |
| 86709 | <1% | 505 | $10K | |
| 84153 | <1% | 453 | $10K | |
| 86592 | <1% | 1,160 | $10K | |
| 0002A | <1% | 957 | $10K | |
| 87276 | <1% | 1,535 | $10K | |
| 96415 | <1% | 211 | $9K | |
| 70488 | <1% | 26 | $9K | |
| 74246 | <1% | 76 | $9K | |
| 93925 | <1% | 77 | $9K | |
| 77066 | Tomosynthesis, mammo | <1% | 132 | $9K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 152 | $8K |
| 72072 | <1% | 148 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 889 | $8K |
| 76870 | <1% | 77 | $8K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 74 | $8K |
| 94729 | <1% | 208 | $8K | |
| 0001A | <1% | 1,073 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 679 | $8K |
| 73523 | <1% | 183 | $8K | |
| 77080 | <1% | 377 | $8K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 555 | $8K |
| 96523 | <1% | 839 | $7K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 92 | $7K |
| 90714 | <1% | 475 | $7K | |
| 84436 | <1% | 352 | $7K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 285 | $7K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 300 | $7K |
| 84403 | <1% | 246 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,301 | $7K |
| 12002 | <1% | 98 | $7K | |
| 85379 | <1% | 424 | $7K | |
| 88185 | <1% | 77 | $7K | |
| 99499 | <1% | 129 | $6K | |
| 82390 | <1% | 231 | $6K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 13 | $6K |
| 82565 | <1% | 439 | $6K | |
| D2330 | <1% | 13 | $6K | |
| 82465 | <1% | 536 | $6K | |
| 84132 | <1% | 630 | $6K | |
| 80143 | <1% | 548 | $6K | |
| 86256 | <1% | 105 | $6K | |
| 86804 | <1% | 243 | $6K | |
| 17110 | <1% | 402 | $5K | |
| 82248 | <1% | 249 | $5K | |
| 87430 | <1% | 598 | $5K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 464 | $5K |
| 84478 | <1% | 519 | $5K | |
| C1776 | Joint device (implantable) | <1% | 15 | $5K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 281 | $5K |
| 94010 | <1% | 336 | $5K | |
| 73600 | <1% | 142 | $5K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 514 | $5K |
| 73620 | <1% | 148 | $5K | |
| 97166 | <1% | 99 | $5K | |
| 82274 | <1% | 199 | $5K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,348 | $5K |
| V2632 | Posterior chamber intraocular lens | <1% | 47 | $5K |
| 86703 | <1% | 449 | $5K | |
| 84450 | <1% | 491 | $5K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 432 | $5K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,560 | $5K |
| 86705 | <1% | 144 | $5K | |
| 73070 | <1% | 197 | $5K | |
| 90686 | <1% | 481 | $5K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 87 | $5K |
| 93242 | <1% | 467 | $4K | |
| 85045 | <1% | 738 | $4K | |
| 86160 | <1% | 29 | $4K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 733 | $4K |
| 82948 | <1% | 1,536 | $4K | |
| 87449 | <1% | 83 | $4K | |
| 11045 | <1% | 22 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,758 | $4K |
| 86762 | <1% | 321 | $4K | |
| 94726 | <1% | 207 | $4K | |
| 87205 | <1% | 908 | $4K | |
| 73522 | <1% | 44 | $4K | |
| 72020 | <1% | 150 | $4K | |
| 70544 | <1% | 15 | $3K | |
| 84480 | <1% | 128 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 402 | $3K |
| 51702 | <1% | 120 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 52 | $3K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 353 | $3K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 25 | $3K |
| 78306 | <1% | 41 | $3K | |
| 0012A | <1% | 330 | $3K | |
| 73552 | <1% | 60 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 50 | $3K |
| 86235 | <1% | 70 | $3K | |
| 83001 | <1% | 70 | $3K | |
| 83520 | <1% | 53 | $3K | |
| A9270 | Non-covered item or service | <1% | 3,483 | $3K |
| 73120 | <1% | 86 | $3K | |
| 82104 | <1% | 351 | $3K | |
| 83037 | <1% | 760 | $3K | |
| 87150 | <1% | 13 | $2K | |
| 82962 | <1% | 1,383 | $2K | |
| 71101 | <1% | 42 | $2K | |
| 29125 | <1% | 61 | $2K | |
| 83921 | <1% | 62 | $2K | |
| J2806 | Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms | <1% | 18 | $2K |
| 86308 | <1% | 195 | $2K | |
| 77417 | <1% | 37 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,004 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 20 | $2K |
| 95910 | <1% | 74 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 45 | $2K |
| 0011A | <1% | 355 | $2K | |
| 88307 | <1% | 18 | $2K | |
| 87075 | <1% | 85 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 294 | $2K |
| 10060 | <1% | 15 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 227 | $2K |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 179 | $2K |
| 76882 | <1% | 60 | $2K | |
| 80185 | <1% | 105 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 23 | $2K |
| 93270 | <1% | 41 | $2K | |
| 84520 | <1% | 139 | $2K | |
| 12011 | <1% | 31 | $2K | |
| 94760 | <1% | 311 | $2K | |
| 92523 | <1% | 21 | $2K | |
| 88108 | <1% | 144 | $2K | |
| 88142 | <1% | 77 | $1K | |
| 77085 | <1% | 88 | $1K | |
| 82009 | <1% | 110 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 63 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 802 | $1K |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | <1% | 164 | $1K |
| 80171 | <1% | 30 | $1K | |
| 86756 | <1% | 215 | $1K | |
| 96416 | <1% | 19 | $1K | |
| 0097U | <1% | 31 | $1K | |
| 93320 | <1% | 18 | $1K | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 151 | $1K |
| Q2039 | Influenza virus vaccine, not otherwise specified | <1% | 103 | $1K |
| 83655 | <1% | 46 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 253 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 225 | $1K |
| 74420 | <1% | 13 | $1K | |
| 87480 | <1% | 114 | $1K | |
| 83002 | <1% | 28 | $1K | |
| 87510 | <1% | 100 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 25 | $1K |
| 84270 | <1% | 61 | $1K | |
| 85384 | <1% | 61 | $1K | |
| 82272 | <1% | 324 | $998.64 | |
| 95909 | <1% | 30 | $994.24 | |
| 72070 | <1% | 13 | $967.10 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 176 | $965.95 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 96 | $960.77 |
| 81490 | <1% | 14 | $955.50 | |
| 85014 | <1% | 138 | $945.64 | |
| 87660 | <1% | 100 | $924.35 | |
| 87338 | <1% | 44 | $901.14 | |
| 85018 | <1% | 126 | $900.98 | |
| 93922 | <1% | 32 | $868.83 | |
| G0008 | Administration of influenza virus vaccine | <1% | 130 | $868.61 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 29 | $833.08 |
| 95886 | <1% | 73 | $757.83 | |
| 82378 | <1% | 15 | $754.52 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 13 | $726.27 |
| 82785 | <1% | 13 | $725.37 | |
| 99195 | <1% | 19 | $720.80 | |
| 87653 | <1% | 42 | $708.60 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 58 | $672.71 |
| 76857 | <1% | 30 | $671.99 | |
| 85660 | <1% | 75 | $650.41 | |
| Q3014 | Telehealth originating site facility fee | <1% | 326 | $639.66 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 29 | $625.70 |
| 93000 | <1% | 45 | $615.76 | |
| 82105 | <1% | 44 | $609.57 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 30 | $587.88 |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 102 | $586.38 |
| 99243 | <1% | 33 | $575.85 | |
| 80050 | General health panel | <1% | 32 | $572.26 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 15 | $547.35 |
| G0403 | Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report | <1% | 37 | $538.45 |
| 0004A | <1% | 70 | $532.83 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 138 | $521.64 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 277 | $519.48 |
| 99205 | Prolong outpt/office vis | <1% | 33 | $518.24 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 32 | $473.29 |
| 90656 | <1% | 19 | $456.74 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 64 | $435.06 |
| 83721 | <1% | 35 | $428.07 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15 | $424.00 |
| 97116 | <1% | 21 | $420.16 | |
| 90633 | <1% | 18 | $414.47 | |
| 90662 | <1% | 33 | $405.24 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 60 | $404.04 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 48 | $400.27 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 17 | $396.20 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 549 | $387.82 |
| 36416 | <1% | 191 | $386.93 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 294 | $383.93 |
| 0064A | <1% | 54 | $372.84 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 58 | $365.61 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 57 | $364.84 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 316 | $357.72 |
| 90632 | <1% | 23 | $348.80 | |
| 83525 | <1% | 14 | $344.44 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 43 | $328.60 |
| 87493 | <1% | 22 | $295.99 | |
| 87081 | <1% | 17 | $289.41 | |
| 97164 | <1% | 25 | $273.17 | |
| 84402 | <1% | 20 | $271.72 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 92 | $267.59 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 330 | $239.86 |
| 0296T | <1% | 14 | $229.50 | |
| 86037 | <1% | 24 | $216.35 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 118 | $214.65 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 118 | $203.00 |
| 84134 | <1% | 13 | $184.75 | |
| 29700 | <1% | 38 | $171.26 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 238 | $167.96 |
| 80178 | <1% | 14 | $154.01 | |
| 85007 | <1% | 19 | $150.48 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 78 | $138.69 |
| 88302 | <1% | 22 | $136.17 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 39 | $107.17 |
| 81003 | <1% | 15 | $104.26 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $97.11 |
| 0003A | <1% | 14 | $86.40 | |
| 86580 | <1% | 30 | $83.97 | |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 15 | $68.39 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 13 | $17.16 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 174 | $0.18 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 21 | $0.02 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 39 | $0.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.